2018 IPO

Twist Bioscience Stock

Synthetic DNA production for specialty chemical compounds and drug development Twist Bioscience Corp.

Sign up today and learn more about Twist Bioscience Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Twist Bioscience Stock

At Twist Bioscience Corporation, they work in service of customers who are changing the world for the better. In fields such as health care, agriculture, industrial chemicals and data storage, by using our synthetic DNA tools, their customers are developing ways to better lives and improve the sustainability of the planet. They believe that the faster their customers succeed, the better for all of them , and Twist Bioscience is uniquely positioned to help accelerate their efforts. Their innovative silicon-based DNA Synthesis Platform provides precision at a scale that we believe is otherwise unavailable to their customers. their platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis and sequencing, providing both the quality and quantity of the tools they need to rapidly realize the opportunity ahead.

Funding History

February 2014$9.1M
May 2014$26.0M
September 2014$10.0M
June 2015$37.0M
January 2016$61.0M
March 2017$33.0M
June 2017$27.0M
April 2018$50.0M



Solange Glaize

Founder & Chief Technology Officer

Bill Peck

Chief Executive Officer

Emily Leproust

Founder & Chief Operating Officer

Bill Banyai

VP Sales and Marketing

Patrick Finn


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: